NOV 03, 2016 10:30 AM PDT

Found in Translation: ST2 From Discovery to Clinical Adoption

Speakers
  • President, Critical Diagnostics
    Biography
      Dr. James V. Snider, Ph.D., has been the President of Critical Care Diagnostics Inc. since August 2005 and serves as its Member of the Management Board. Prior to joining CCD in August 2005, Dr. Snider Served as a Executive Vice President of Business and Operations of Intelligent Medical Devices Inc. Dr. Snider joined Intelligent MD in October 2001 as Vice President of Marketing and Business Development. Prior to IMD, Dr. Snider served a series of marketing and product development positions at Applied Biosystems (ABI). In his last role at ABI, he managed the Sample Preparation Systems product line and team from genesis through product launch and successfully established it in the market. Before his eight-year tenure at AB, Dr. Snider served as Senior Scientist at Biotech Research Laboratories, a contracts and service research company specializing in retroviral technologies. He performed his post-doctoral research as a fellow in the Biological Response Modifiers Program at the Frederick Cancer Research & Development Center of the National Cancer Institute. Dr. Snider holds a BS in chemistry from Grand Valley State University, a PhD in chemistry from the University of South Carolina and an MBA in technology management from the University of Phoenix.

    Abstract:

    Laboratory tests come into existence through a variety of processes but regardless of the genesis all share a certain set of requirements. These include discovery, development, validation, regulatory clearance and market adoption. ST2 is a protein biomarker that was discovered in a gene expression exploration analysis to be involved in cardiac disease and to potentially have clinical value in managing patients with cardiac disease. Following this discovery Critical Diagnostics developed an in vitro diagnostic assay to accurately measure ST2 and performed the necessary clinical studies to determine the clinical value proposition. This information was used to pursue and obtain regulatory approval and the test is now available in most of the world. This lecture will cover the processes and issues from taking a biomarker target from discovery through to commercialization.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources